129 related articles for article (PubMed ID: 32481524)
1. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in
Lee SH; Jeon Y; Kang JH; Jang H; Lee H; Kim SY
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32481524
[TBL] [Abstract][Full Text] [Related]
2. Reply to Krupenko et al. Comment on "Lee et al. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer
Lee SH; Jeon Y; Kang JH; Jang H; Hong KM; Hong D; Lee H; Kim SY
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066916
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion.
Kang JH; Lee SH; Lee JS; Nam B; Seong TW; Son J; Jang H; Hong KM; Lee C; Kim SY
Oncotarget; 2016 Aug; 7(31):49397-49410. PubMed ID: 27384481
[TBL] [Abstract][Full Text] [Related]
4. Is ALDH1L1 Elevated in Lung Cancer? Comment on: Lee, S.-H.; et al. "The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer"
Krupenko SA; Sharma J
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918472
[TBL] [Abstract][Full Text] [Related]
5. Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.
Park J; Shim JK; Kang JH; Choi J; Chang JH; Kim SY; Kang SG
Neuro Oncol; 2018 Jun; 20(7):954-965. PubMed ID: 29294080
[TBL] [Abstract][Full Text] [Related]
6. Structural identification and comprehension of human ALDH1L1-Gossypol complex.
Han CW; Lee HN; Jeong MS; Kim HY; Jang SB
Biochem Biophys Res Commun; 2024 Jun; 726():150306. PubMed ID: 38917634
[TBL] [Abstract][Full Text] [Related]
7. Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status.
Zhang J; Nannapaneni S; Wang D; Liu F; Wang X; Jin R; Liu X; Rahman MA; Peng X; Qian G; Chen ZG; Wong KK; Khuri FR; Zhou W; Shin DM
Oncotarget; 2017 Aug; 8(35):59008-59022. PubMed ID: 28938614
[TBL] [Abstract][Full Text] [Related]
8. Aldehyde dehydrogenase is used by cancer cells for energy metabolism.
Kang JH; Lee SH; Hong D; Lee JS; Ahn HS; Ahn JH; Seong TW; Lee CH; Jang H; Hong KM; Lee C; Lee JH; Kim SY
Exp Mol Med; 2016 Nov; 48(11):e272. PubMed ID: 27885254
[TBL] [Abstract][Full Text] [Related]
9. Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis.
Wang ZD; Wei SQ; Wang QY
Am J Cancer Res; 2015; 5(11):3339-49. PubMed ID: 26807315
[TBL] [Abstract][Full Text] [Related]
10. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
11. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
12. Loss of ALDH1L1 folate enzyme confers a selective metabolic advantage for tumor progression.
Krupenko SA; Krupenko NI
Chem Biol Interact; 2019 Apr; 302():149-155. PubMed ID: 30794800
[TBL] [Abstract][Full Text] [Related]
13. Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
Rushing BR; Fogle HM; Sharma J; You M; McCormac JP; Molina S; Sumner S; Krupenko NI; Krupenko SA
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500483
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of MEK and p38 impairs tumor growth in
Sunaga N; Miura Y; Tsukagoshi Y; Kasahara N; Masuda T; Sakurai R; Kaira K; Hisada T
Oncol Lett; 2019 Mar; 17(3):3569-3575. PubMed ID: 30867799
[TBL] [Abstract][Full Text] [Related]
15. CHIP E3 ligase mediates proteasomal degradation of the proliferation regulatory protein ALDH1L1 during the transition of NIH3T3 fibroblasts from G0/G1 to S-phase.
Khan QA; Pediaditakis P; Malakhau Y; Esmaeilniakooshkghazi A; Ashkavand Z; Sereda V; Krupenko NI; Krupenko SA
PLoS One; 2018; 13(7):e0199699. PubMed ID: 29979702
[TBL] [Abstract][Full Text] [Related]
16. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC.
Xia M; Li X; Diao Y; Du B; Li Y
Transl Oncol; 2021 Jan; 14(1):100920. PubMed ID: 33137541
[TBL] [Abstract][Full Text] [Related]
18. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
19. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
20. Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC.
Lee S; Lee JS; Seo J; Lee SH; Kang JH; Song J; Kim SY
Sci Rep; 2018 Oct; 8(1):15707. PubMed ID: 30356107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
